↓ Skip to main content

Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis

Overview of attention for article published in Frontiers in immunology, July 2021
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users

Readers on

mendeley
30 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis
Published in
Frontiers in immunology, July 2021
DOI 10.3389/fimmu.2021.638678
Pubmed ID
Authors

Ping Li, Lili Zhou, Shiguang Ye, Wenjun Zhang, Junbang Wang, Xiaochen Tang, Jie Liu, Yangyang Xu, Wenbin Qian, Aibin Liang

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 30 100%

Demographic breakdown

Readers by professional status Count As %
Other 3 10%
Student > Master 3 10%
Unspecified 2 7%
Student > Bachelor 2 7%
Student > Ph. D. Student 2 7%
Other 6 20%
Unknown 12 40%
Readers by discipline Count As %
Medicine and Dentistry 9 30%
Biochemistry, Genetics and Molecular Biology 3 10%
Unspecified 2 7%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Nursing and Health Professions 1 3%
Other 1 3%
Unknown 13 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 July 2021.
All research outputs
#16,734,944
of 25,392,582 outputs
Outputs from Frontiers in immunology
#18,347
of 31,541 outputs
Outputs of similar age
#255,027
of 446,072 outputs
Outputs of similar age from Frontiers in immunology
#819
of 1,418 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 31,541 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 446,072 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,418 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.